Seven Innovative Biopharma Companies Secure New Funding Rounds

InxMed

Financing Round: Series C

Financing Amount: Over 34 Million US Dollars

On August 22, InxMed announced that it had recently completed a Series C financing round of over 34 million US dollars. This round of financing was led by Fosun Health Capital, with participation from investors such as StarVest Capital, Chengxiang Capital, and Kunlun Capital. Existing shareholder Enran Venture Capital continued to increase its investment. Founded in 2018, InxMed is a biotechnology company in the late clinical stage, committed to revolutionizing the current treatment paradigm for solid tumors with limited therapeutic options and addressing emerging treatment resistance caused by tumor defense systems.With theFAK Target Mechanism and Related PathwaysA large number of translational medicine studies have been conducted. InxMed has developed a pipeline layout targeting multiple tumor types with different targets, mechanisms, and drug combinations, and several clinical trials are progressing rapidly. Additionally,InxMed has developed multiple innovative drug candidates targeting the tumor defense system, featuring high differentiation and synergistic effects. Since its establishment, the company has completed multiple rounds of financing, totaling over 130 million US dollars.

Vivatides Therapeutics

Financing Round:Seed Round

Financing Amount:Tens of Millions of Dollars

On August 20, Vivatides Therapeutics announced the completionTens of Millions of Dollars in Seed Round Financing Led by Apricot Capital and Followed by Qiming Venture Partners. The funds raised in this round are mainlyFor the development of preclinical non-hepatic targeting small nucleic acid platforms and pipelines。Vivatides Therapeutics was founded in 2025, based on its self-developed liver-targeted delivery technology platform,Focusing on the targeted delivery of small nucleic acid drugs in non-liver tissues, aiming to break through the technical bottleneck that traditional small nucleic acid drugs are limited to liver delivery.，To meet unmet medical needs。Core members of the company's international team have many years of R&D experience in the small nucleic acid field. They have led or been deeply involved in the development of multiple hepatic-targeted nucleic acid drug pipelines and possess practical experience in the development of both extrahepatic antisense oligonucleotides (ASO) and siRNA pipelines.

Belhaven Biopharma

Financing Round: Series A

Financing Amount: 10 Million US Dollars

On August 20, Belhaven Biopharma announced the completion of an oversubscribed Series A financing round, with an initial fundraising target of $10 million. Belhaven is a clinical-stage drug development company focused on developing life-saving medications that enable rapid, effective, and painless administration through a simple, dry powder, single-use intranasal delivery device. The proceeds from the Series A round will be used to complete the clinical development and commercial-scale production of Nasdepi, as well as prepare for the submission of a New Drug Application (NDA) to the U.S. FDA. Nasdepi is a...Dry powder, needle-free, heat-stable epinephrine therapy for anaphylactic shock emergency treatment. This product aims to address key limitations of current auto-injector epinephrine delivery methods, including needle phobia, temperature sensitivity, and complex device operation instructions.Through the dry powder intranasal delivery technology, Nasdepi can achieve rapid and reliable drug absorption during an allergic reaction in patients, regardless of body position or nasal congestion.

XunSheng Bio

Financing Round: Undisclosed

Financing Amount: Undisclosed

On August 18, XunSheng Biopharma announced the completion of a new round of financing, led by Origin Innovation Capital. Established in March 2021, XunSheng Biopharma is an innovative biopharmaceutical company primarily focused on addressing challenges in solid tumor treatments. The company combines neoantigen nucleic acid technology with cell therapy to comprehensively activate the immune system and accelerate breakthrough solutions for curing cancer. Its therapeutic nucleic acid vaccine development platform focuses on precancerous lesions and cervical cancer caused by HPV infections, with its first product...HPV Therapeutic Nucleic Acid Vaccine(AVL-101) has multiple effects in prevention and treatment. In addition, the TILs cell therapy development platform of Xunsheng Medicine aims to target malignant solid tumors such as liver cancer and cervical cancer. The first Re-TIL cell therapy product is currently undergoing Phase 1 clinical trials, which are nearing completion. So far, the clinical data has been promising, and Phase 2 clinical trials are planned to be initiated by the end of the year.

Anocca

Financing Round: Undisclosed

Financing Amount: 440 million Swedish kronor

On August 18, clinical-stage T-cell immunotherapy company Anocca announced the completion of approximately 440 million Swedish kronor (about 46 million US dollars) in financing. The new funds will be used to promote VIDAR-1.(For pancreatic cancerKRASMutant Gene-Edited TCR-T Cell TherapyThe early clinical development, and advance the company's preclinical pipeline. Anocca is committed to developing a library of T-cell receptor engineered T-cell (TCR-T) therapies to redefine the treatment of solid tumors and other difficult-to-treat diseases (including infectious and autoimmune diseases).

Mirugen

Financing Round: Seed Round

Financing Amount: 4.5 Million AUD

On August 18, Mirugen announced the successful completion of a AUD 4.5 million seed funding round. The proceeds from this round will be used to support the translational development of Mirugen's core technology and its lead project, a therapy for retinitis pigmentosa. The root cause of progressive vision loss in patients with retinitis pigmentosa is the severe depletion of photoreceptor cells (light-sensitive cells) in the eye. Mirugen’s lead candidate therapy targets newly generated stem cells called Müller glial cells in the eye to replace and regenerate damaged photoreceptors. If the project succeeds in development, the technology is expected to also be applicable to major blinding diseases globally, including age-related macular degeneration.

Koning Bio

Financing Round: Series A

Financing Amount: Tens of Millions of Yuan

On August 18, Conzyme Biotech announced the completion of the first closing of its Series A financing round worth tens of millions of RMB. This round of financing will support Conzyme Biotech's development in multiple indications, including advancing its core pipelines P001X and P002 in clinical studies for osteoarthritis and dry eye disease. P001X is based on Conzyme Biotech’s polymer design platform.Simulating the Structure of Natural Lubricin Protein and Its Interfacial Lubrication Role in Joints with Unique Synthetic Polymers, improving the osteoarthritis process through a novel mechanism of action. The product has demonstrated excellent preclinical efficacy and safety in preclinical studies and can be scaled up for production via chemical synthesis. Conner Biotech has multiple pipelines under research for dry eye syndrome, among which P002 is another breakthrough result based on its innovative technology platform. The product, employing a lubricin-mimetic strategy, achieves long-lasting ocular surface lubrication and tissue protection through unique polymer design.

References:

[1]Official websites of various companies and publicly available information